Raymond James lowered the firm’s price target on Haemonetics (HAE) to $115 from $120 and keeps a Strong Buy rating on the shares. Shares sold off sharply following the Q3 results, but Raymond James continues to think the business can demonstrate that the underlying core is capable of high-single digit top-line growth and double-digit EPS growth and far underappreciated, the analyst tells investors in a research note. The firm believes that the near term sales declines are “growing pains” and not structural headwinds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics price target lowered to $90 from $115 at Mizuho
- Haemonetics price target lowered to $95 from $108 at Barrington
- Haemonetics downgraded to Underperform from Neutral at BofA
- Haemonetics price target lowered to $100 from $125 at JMP Securities
- Haemonetics Reports Strong Q3 Financial Results